查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1523027

艾森曼格症候群治療市場報告：2030 年趨勢、預測與競爭分析

Eisenmenger Syndrome Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

艾森曼格症候群治療的趨勢與預測

預計 2024 年至 2030 年，全球艾森曼格氏症治療市場將以 5.8% 的複合年成長率成長。該市場的主要促進因素是受艾森曼格症候群影響的患者數量不斷增加，以及對先進藥物開發相關研發活動的日益關注。全球艾森曼格症候群治療市場前景廣闊，醫院藥局、線上藥局和零售藥局市場充滿機會。

艾森曼格症候群的分段治療

本研究按藥物類型、分銷管道和地區對全球艾森曼格症候群治療進行了預測。

艾森曼格症候群治療市場洞察

Lucintel 預測，內皮素受體拮抗劑預計將在預測期內實現最高成長，因為它們對各種併發症的治療具有廣泛的影響，而且成本可能較低。

在這個市場中，醫院藥房預計將在預測期內實現最高成長。

由於慢性病的增加和先進醫療技術的高採用率，北美在預測期內仍將是最大的地區。

常問問題

Q1.市場成長預測是多少：

A1. 2024 年至 2030 年，全球艾森曼格氏症候群治療市場預計將以 5.8% 的複合年成長率成長。

Q2. 影響市場成長的主要促進因素是：

A2. 該市場的主要驅動力是受艾森曼格氏症候群影響的患者數量不斷增加，以及對與先進藥物開發相關的研發活動的日益關注。

Q3.市場的主要細分市場是：

A3. 艾森曼格症候群治療市場未來性廣闊，醫院藥局、網路藥局和零售藥局市場充滿機會。

Q4.市場的主要企業是：

A4. 生產艾森曼格氏症候群治療藥物的主要企業如下：

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預測，內皮素受體拮抗劑將在預測期內表現出最高的成長，因為它們對各種併發症的治療具有廣泛的影響，而且成本可能較低。

Q6.未來五年預計哪些地區的市場成長最大？

A6. 由於慢性病的增加和先進醫療技術的高採用率，預計北美在預測期內仍將是最大的地區。

Q7. 可以客製化報告嗎？

A7。

目錄

第1章執行摘要

第2章全球艾森曼格症候群治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球艾森曼格氏症候群治療市場趨勢（2018-2023）與預測（2024-2030）
  • 艾森曼格症候群治療的全球市場（按藥物類型）
    • 抗心律不整藥物
    • 抗凝血物
    • 內皮素受體拮抗劑
    • 其他
  • 按分銷管道分類的全球艾森曼格症候群治療市場
    • 醫院藥房
    • 網路藥房
    • 零售藥房

第4章 2018-2030年區域市場趨勢及預測分析

  • 艾森曼格症候群治療市場（按地區）
  • 北美艾森曼格症候群治療市場
  • 歐洲艾森曼格症候群治療市場
  • 亞太地區艾森曼格症候群治療市場
  • 其他地區艾森曼格症候群治療市場

第5章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
  • 全球艾森曼格氏症候群治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球艾森曼格症候群治療市場的產能
    • 全球艾森曼格氏症候群治療市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer
簡介目錄

Eisenmenger Syndrome Treatment Trends and Forecast

The future of the global eisenmenger syndrome treatment market looks promising with opportunities in the hospital pharmacies, online pharmacies, and retail pharmacies markets. The global eisenmenger syndrome treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are growing number of patients suffering from eisenmenger syndrome and rising focus on r&d activities related to the development of advanced drugs.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Eisenmenger Syndrome Treatment by Segment

The study includes a forecast for the global eisenmenger syndrome treatment by drug type, distribution channel, and region.

Eisenmenger Syndrome Treatment Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Antiarrhythmic Agents
  • Blood Thinning Agents
  • Endothelin Receptor Antagonist
  • Others

Eisenmenger Syndrome Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Eisenmenger Syndrome Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Eisenmenger Syndrome Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies eisenmenger syndrome treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the eisenmenger syndrome treatment companies profiled in this report include-

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer

Eisenmenger Syndrome Treatment Market Insights

Lucintel forecasts that endothelin receptor antagonist is expected to witness the highest growth over the forecast period due to their broader impact on managing various complications and potentially lower cost.

Within this market, hospital pharmacies is expected to witness the highest growth over the forecast period.

North America will remain the largest region over the forecast period due to increasing incidences of chronic diseases and higher adoption rate of advanced medical technologies in the region.

Features of the Global Eisenmenger Syndrome Treatment Market

Market Size Estimates: Eisenmenger syndrome treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Eisenmenger syndrome treatment market size by drug type, distribution channel, and region in terms of value ($B).

Regional Analysis: Eisenmenger syndrome treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, distribution channels, and regions for the eisenmenger syndrome treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the eisenmenger syndrome treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for eisenmenger syndrome treatment market?

Answer: The global eisenmenger syndrome treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the eisenmenger syndrome treatment market?

Answer: The major drivers for this market are growing number of patients suffering from eisenmenger syndrome and rising focus on r&d activities related to the development of advanced drugs.

Q3. What are the major segments for eisenmenger syndrome treatment market?

Answer: The future of the eisenmenger syndrome treatment market looks promising with opportunities in the hospital pharmacies, online pharmacies, and retail pharmacies markets.

Q4. Who are the key eisenmenger syndrome treatment market companies?

Answer: Some of the key eisenmenger syndrome treatment companies are as follows:

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer

Q5. Which eisenmenger syndrome treatment market segment will be the largest in future?

Answer: Lucintel forecasts that endothelin receptor antagonist is expected to witness the highest growth over the forecast period due to their broader impact on managing various complications and potentially lower cost.

Q6. In eisenmenger syndrome treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing incidences of chronic diseases and higher adoption rate of advanced medical technologies in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the eisenmenger syndrome treatment market by drug type (antiarrhythmic agents, blood thinning agents, endothelin receptor antagonist, and others), distribution channel (hospital pharmacies, online pharmacies, and retail pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Eisenmenger Syndrome Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Eisenmenger Syndrome Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Eisenmenger Syndrome Treatment Market by Drug Type
    • 3.3.1: Antiarrhythmic Agents
    • 3.3.2: Blood Thinning Agents
    • 3.3.3: Endothelin Receptor Antagonist
    • 3.3.4: Others
  • 3.4: Global Eisenmenger Syndrome Treatment Market by Distribution Channel
    • 3.4.1: Hospital Pharmacies
    • 3.4.2: Online Pharmacies
    • 3.4.3: Retail Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Eisenmenger Syndrome Treatment Market by Region
  • 4.2: North American Eisenmenger Syndrome Treatment Market
    • 4.2.1: North American Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.2.2: North American Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
  • 4.3: European Eisenmenger Syndrome Treatment Market
    • 4.3.1: European Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.3.2: European Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
  • 4.4: APAC Eisenmenger Syndrome Treatment Market
    • 4.4.1: APAC Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.4.2: APAC Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
  • 4.5: ROW Eisenmenger Syndrome Treatment Market
    • 4.5.1: ROW Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.5.2: ROW Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Region
  • 6.2: Emerging Trends in the Global Eisenmenger Syndrome Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Eisenmenger Syndrome Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Eisenmenger Syndrome Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Actelion Pharmaceuticals
  • 7.2: Gilead Sciences
  • 7.3: Pfizer
  • 7.4: Teva Pharmaceutical Industries
  • 7.5: AstraZeneca
  • 7.6: Novartis
  • 7.7: Merck & Co
  • 7.8: GlaxoSmithKline
  • 7.9: Mylan
  • 7.10: Bayer